Despite the fact that an association has been reported between the mutational status of genes of the EGFR signaling pathway and the prognosis of sCRC patients [38, 50–53], to the best of our knowledge, this is the first time that a scoring system based on combined assessment of the TNM stage at diagnosis and the BRAF mutational status is proposed, for the identification of sCRC patients undergoing complete tumor resection who are still at high risk of recurrence of the disease in the first 2-years after diagnosis (score 2). The gene discussed is BRAF; the disease is neoplasm.